Tibet Aim Pharm

Tibet Aim Pharm EBIT Margin

The EBIT Margin (Operating Margin) of Tibet Aim Pharm (002826.SZ) as of Nov 19, 2026 is 15.50 %. In the previous year, EBIT Margin (Operating Margin) was 9.43 % — a change of 64.25% (higher).

EBIT Margin

15.50 %

YoY

64.25%

Last updated:

EBIT Margin (Operating Margin) of Tibet Aim Pharm is 2025 15.50 % . EBIT Margin (Operating Margin) of Tibet Aim Pharm was 2024 9.43 % . It decreases by 64.25% higher compared to the previous year.

Tibet Aim Pharm's operating (EBIT) margin stands at 15.5%, up from 6.7% several years earlier.

The Tibet Aim Pharm EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
5.49 CNY
Jan 1, 2019
8.62 CNY
Jan 1, 2020
7.16 CNY
Jan 1, 2021
6.70 CNY
Jan 1, 2022
6.50 CNY
Jan 1, 2023
3.52 CNY
Jan 1, 2024
9.43 CNY
Jan 1, 2025
15.50 CNY
The Tibet Aim Pharm EBIT Margin history
YEAREBIT MarginYoY
15.50 %+64.25%
9.43 %+167.74%
3.52 %-45.83%
6.50 %-2.97%
6.70 %-6.32%
7.16 %-17.00%
8.62 %+56.92%
5.49 %-67.90%
17.12 %+64.07%
10.43 %-20.36%
13.10 %+27.10%
10.31 %+15,906.20%
0.06 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tibet Aim Pharm Stock analysis

What does Tibet Aim Pharm do? Tibet Aim Pharm., Inc. generates revenue through the research, development, production, and sale of chemical drugs and Chinese medicines. The company's self-manufacturing medicine portfolio features miglitol tablets, hongjinxiaojie tablet, aceclofenac enteric-coated tablets, montmorillonite powder, and domperidone tablets. Third-party medicine offerings include gualoupi injection, nalmefene hydrochloride injection, oral liquid for children, cefotaxime sodium for injection, and carbetocin injection. Domestic and overseas markets are the primary sales channels for these products, with the company distributing its medicines across both segments. The firm's self-manufacturing medicines are sold to domestic healthcare providers and consumers, while third-party medicine products are distributed through partnerships with other pharmaceutical entities. The company's product mix caters to various therapeutic areas, including gastrointestinal, cardiovascular, and pediatric treatments. Revenue streams are derived from direct sales of its proprietary drugs and third-party agreements for distribution. Tibet Aim Pharm., Inc. serves the domestic Chinese market and international markets with its chemical drugs and Chinese medicines. The company's product range targets healthcare institutions, pharmacies, and end consumers for self-manufacturing medicines, while third-party medicine products are supplied to distributors and healthcare facilities. The business model relies on manufacturing and distributing a diverse portfolio of pharmaceutical products to meet market demand. Tibet Aim Pharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tibet Aim Pharm stock

EBIT Margin (Operating Margin) of Tibet Aim Pharm is 15.50 % in 2025.

EBIT Margin (Operating Margin) of Tibet Aim Pharm changed from 9.43 % to 15.50 %, representing a 64.25% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Tibet Aim Pharm since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Tibet Aim Pharm with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Tibet Aim Pharm

All Key Metrics — Tibet Aim Pharm